ÀÇ·á½Ã¼³Æó·Å(Healthcare-associated pneumonia) ȯÀÚÀÇ ÁßÁõµµ ¿¹Ãø¿¡ ÀÖ¾î ÇÁ·ÎÄ®½ÃÅä´Ñ ³óµµ ÃøÁ¤ÀÇ À¯¿ë¼º
Usefulness of Procalcitonin Levels in Assessing Severity in Patients with Healthcare-associated Pneumonia

´ëÇÑÀÀ±ÞÀÇÇÐȸÁö 2014³â 25±Ç 3È£ p.299 ~ p.306

¹ÚÁ¾È£(Park Jong-Ho) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ÀÀ±ÞÀÇÇб³½Ç
±èÁ¾¿ø(Kim Jong-Won) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ÀÀ±ÞÀÇÇб³½Ç
¹Ú»ó¹Î(Park Sang-Min) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ÀÀ±ÞÀÇÇб³½Ç
ÀÌ°æ·æ(Lee Kyeong-Ryong) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ÀÀ±ÞÀÇÇб³½Ç
¹Ú»ó¿À(Park Sang-O) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ÀÀ±ÞÀÇÇб³½Ç
¹é±¤Á¦(Baek Kwang-Je) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ÀÀ±ÞÀÇÇб³½Ç
È«´ë¿µ(Hong Dae-Young) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ÀÀ±ÞÀÇÇб³½Ç

Abstract

Purpose: Healthcare-associated pneumonia (HCAP) has been proposed as a new category of pneumonia. However, studies of HCAP patients in Korea are limited. The aim of this study was to investigate the usefulness of procalcitonin (PCT) in assessment of the severity of HCAP patients.

Methods: We conducted a retrospective study of patients with HCAP who were hospitalized between August 2009 and July 2013. We evaluated white blood cell, C-reactive protein, and PCT, along with the pneumonia severity index score and CURB-65 in HCAP patients.

Results: The mean age of the 78 patients was 77.5 years. The PSI and CURB-65 scores showed similar trends of increasing mortality with worsening risk class in HCAP patients. The median PCT level was significantly higher in the non-survival group than in the survival group (3.1 ng/mL vs 0.4 ng/mL, p=0.003). The PCT level was significantly higher in patients with positive blood cultures (0.95 ng/mL vs 0.36 ng/mL, p=0.010). PCT levels rose consistently asPSI class advanced from class I/II/III to class V (p<0.001).In receiver operating characteristic curves analysis for prediction of mortality, PCT level had an area under the curve (AUC) of 0.655 (95% confidence interval 0.523-0.786).

Conclusion: We found that measurement of PCT in the emergency department may provide helpful information for use in assessment of HCAP patients.

Ű¿öµå

Pneumonia, Severity of illness index, Procalcitonin
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå